mTOR kinase inhibitors as potential cancer therapeutic drugs.

The mammalian target of rapamycin (mTOR) plays a critical role in the positive regulation of cell growth and survival primarily through direct interaction with raptor (forming mTORC complex 1; mTORC1) or rictor (forming mTOR complex 2; mTORC2). The mTOR axis is often activated in many types of cancer and thus has become an attractive cancer therapeutic target. The modest clinical anticancer activity of conventional mTOR allosteric inhibitors, rapamycin and its analogs (rapalogs), which preferentially inhibit mTORC1, in most types of cancer, has encouraged great efforts to develop mTOR kinase inhibitors (TORKinibs) that inhibit both mTORC1 and mTORC2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogs. Several TORKinibs have been developed and actively studied pre-clinically and clinically. This review will highlight recent advances in the development and research of TORKinibs and discuss some potential issues or challenges in this area.

[1]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[2]  D. Guertin,et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.

[3]  P. Houghton,et al.  Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin , 2011, Molecular Cancer Therapeutics.

[4]  V. Mieulet,et al.  mTORC2 is the hydrophobic motif kinase for SGK1. , 2008, The Biochemical journal.

[5]  H. Zhang,et al.  Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. , 2012, Journal of hepatology.

[6]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[7]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[8]  C. García-echeverría.  Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. , 2010, Bioorganic & medicinal chemistry letters.

[9]  S. Elledge,et al.  Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. , 2013, Cancer research.

[10]  J. Gera,et al.  Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. , 2010, Blood.

[11]  X. Zheng,et al.  Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. , 2011, Drug discovery today.

[12]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[13]  Xiaojin Shi,et al.  Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study , 2013, Investigational New Drugs.

[14]  B. Weigelt,et al.  PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs , 2011, Oncogene.

[15]  Linette Ruston,et al.  Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. , 2013, Bioorganic & medicinal chemistry letters.

[16]  D. Sabatini,et al.  Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. , 2010, Journal of medicinal chemistry.

[17]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[18]  Charles P. Lin,et al.  Defining the role of TORC1/2 in multiple myeloma. , 2011, Blood.

[19]  A. Zask,et al.  Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. , 2010, Current opinion in drug discovery & development.

[20]  J. Baselga,et al.  Dual Mtorc1/2 and Her2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-her2 Therapy Statement of Translational Relevance , 2022 .

[21]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[22]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[23]  Novel inhibitors of mTORC1 and mTORC2. , 2010, Current opinion in investigational drugs.

[24]  F. Khuri,et al.  Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.

[25]  S. Keir,et al.  Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[26]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[27]  Lin Wang,et al.  Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. , 2012, Neoplasia.

[28]  A. Nowak,et al.  The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer , 2012, International reviews of immunology.

[29]  L. Platanias,et al.  Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells , 2010, Proceedings of the National Academy of Sciences.

[30]  Shi-Yong Sun,et al.  Enhancing mTOR-targeted cancer therapy , 2009, Expert opinion on therapeutic targets.

[31]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[32]  K. Baggerly,et al.  Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. , 2010, Blood.

[33]  P. Sorger,et al.  Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics* , 2012, The Journal of Biological Chemistry.

[34]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[35]  N. Demartines,et al.  The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. , 2011, Biochemical and biophysical research communications.

[36]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[37]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[38]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[40]  Barry R Davies,et al.  Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). , 2012, Cancer research.

[41]  D. Sabatini,et al.  Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer , 2011 .

[42]  Jing Chen,et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.

[43]  Kevin Curran,et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. , 2009, Cancer research.

[44]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[45]  Keunwook Lee,et al.  Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia , 2012, The Journal of experimental medicine.

[46]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[47]  R. Abraham,et al.  The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy , 2007, Clinical Cancer Research.

[48]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[49]  E. Raymond,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma , 2012, British Journal of Cancer.

[50]  F. Khuri,et al.  Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy , 2008, Cancer biology & therapy.

[51]  Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.

[52]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[53]  Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells , 2012, BMC Cancer.

[54]  D. Guertin,et al.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy , 2010, Oncogene.

[55]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[56]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[57]  B. Hennessy,et al.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. , 2011, The Journal of clinical investigation.

[58]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[59]  C. Rommel,et al.  Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia , 2013, Leukemia.

[60]  Robert T Abraham,et al.  Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.

[61]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[62]  J. Weiss,et al.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. , 2011, Cancer research.

[63]  F. Sinicrope,et al.  Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1* , 2011, The Journal of Biological Chemistry.

[64]  R. Amato,et al.  A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer , 2009, Cancer.

[65]  D. Alessi,et al.  New Insights into mTOR Signaling: mTORC2 and Beyond , 2009, Science Signaling.

[66]  K. Flatten,et al.  Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. , 2012, Blood.

[67]  J. Gera,et al.  The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance* , 2012, The Journal of Biological Chemistry.